Skip to main content
. 2023 May 2;13(5):626. doi: 10.3390/metabo13050626

Figure 2.

Figure 2

Possible main targets of pemafibrate in conditions of dyslipidemia resulting from visceral obesity, metabolic syndrome, and NAFLD/NASH. Modified from a Figure in Reference [34]. * Both ApoC-III and ANGPTL3 inhibit LPL activity. ⍐: Increase ⍗: Decrease.